Sign in
Taking peoplePhase 4

Metformin compared with glyburide for gestational diabetes in pregnancy

Compares metformin and glyburide for blood sugar control in pregnant women with gestational diabetes.

Key facts

Who runs it
Nishtar Medical University
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Comparison of Metformin Versus Glyburide for Blood Sugar Control in Women With Gestational Diabetes
Status
Recruiting
Phase
Phase 4
People taking part
92 people, planned
Started
18 Apr 2026
Planned end
17 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Metformin
  • Glyburide
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with diabetes that started in pregnancy (gestational diabetes) who need medicine to control blood sugar. It compares metformin with glyburide.

Age
18 to 45 years
Sex
Women only
Disease stage
Gestational diabetes that needs drug treatment, at 13 to 33 weeks of pregnancy, checked by history and ultrasound. The summary says one baby only (singleton pregnancy).

Main reasons for not taking part

  • Diabetes known before this pregnancy
  • Serum creatinine above 1.2 mg / dl (a kidney blood test)
  • Long-term liver disease
  • Allergy to the study medicines

This trial only enrols pregnant participants. The registry sentence this rests on: Gestational age between 13 - 33 weeks based on history and obstetric ultrasonography

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Gestational diabetes requiring drug treatment
  • Gestational age between 13 - 33 weeks based on history and obstetric ultrasonography

Who cannot take part

  • Known cases of diabetes mellitus
  • Chronic liver disease
  • Hypersensitivity to study medications
  • Serum creatinine > 1.2 mg / dl

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

This trial is currently available in Pakistan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this randomized clinical trial is to compare metformin and glyburide for controlling blood sugar in pregnant women with gestational diabetes mellitus (GDM) who require treatment with oral medication.

Read full original descriptionShow less

The main question the study aims to answer is:

Q: Is treatment failure less common with metformin or glyburide in pregnant women with GDM?

The study will include 92 pregnant women aged 18-45 years with a singleton pregnancy, diagnosed with GDM between 13 and 33 weeks of pregnancy and requiring medication to control blood sugar. Participants will be randomly assigned to one of two treatment groups.

Participants in the metformin group will receive metformin, starting at 850 mg once daily and increased to a maximum of 2,550 mg per day according to their blood sugar levels.

Participants in the glyburide group will receive glyburide, starting at 2.5 mg twice daily and increased according to their blood sugar levels, up to a maximum of 20 mg per day.

Blood glucose levels will be monitored regularly using a glucometer. Treatment will be considered successful when at least 80% of the recorded blood glucose measurements are within the target range. Treatment failure will be defined as fewer than 80% of blood glucose measurements being within the target range after up to 4 weeks of treatment. Participants who have treatment failure or cannot continue the assigned medication because of adverse effects will be switched to insulin therapy.

Participants will be followed during pregnancy until delivery. The study will record treatment failure as the primary outcome and will also assess maternal outcomes, including preeclampsia, polyhydramnios, and preterm delivery, as well as newborn outcomes including macrosomia and the need for admission to a neonatal intensive care unit (NICU).

The study will determine whether metformin or glyburide provides better blood sugar control and reduces the need to switch to insulin in pregnant women with gestational diabetes.

The 2 groups in the trial

  • MetforminExisting treatment, for comparison

    Participants will receive metformin orally, once daily

  • GlyburideTreatment being tested

    Participants will receive glyburide orally, twice daily

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Metformin Versus Glyburide in the Control of Gestational Diabetes Mellitus
Plain-language title
Metformin compared with glyburide for gestational diabetes in pregnancyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07802561, who can take part
Record updated
3 September 2026